Vivinex Impress XY1-EM vs RayOne EMV
ConditionCataract
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-80
SponsorMedical University of Bialystok
About this trial
Comparison of the outcomes of bilateral implantation of extended depth of vision (EDOF) intraocular lenses (IOLs): the Rayone EMV and the Vivinex Impress XY1-EM in patients with cataract
Eligibility criteria
Qualifiers
age-related bilateral cataract
age 21 or older
visual acuity > 0.05
axial length: 22.0 - 26.0 mm
Disqualifiers
active ocular disease (e.g. chronic severe uveitis, proliferative diabetic retinopathy, chronic glaucoma not responsive to medication)
relevant other ophthalmic diseases such as pseudoexfoliation syndrome (PEX), intraoperative floppy iris syndrome (IFIS)
corneal decompensation or corneal endothelial cell insufficiency
previous ocular surgery or trauma
Trial design
Treatments tested in this trial
- RayOne EMV
- Vivinex Impress
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov